Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass Is Half Full
- PMID: 35486083
- PMCID: PMC9116347
- DOI: 10.1513/AnnalsATS.202111-1315ED
Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass Is Half Full
Comment on
-
Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases.Ann Am Thorac Soc. 2022 May;19(5):737-745. doi: 10.1513/AnnalsATS.202104-466OC. Ann Am Thorac Soc. 2022. PMID: 34739359
References
-
- Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med . 2018;198:e44–e68. - PubMed
-
- Hopkins RB, Burke N, Fell C, Dion G, Kolb M. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J . 2016;48:187–195. - PubMed
-
- Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med . 2016;193:1161–1167. - PubMed
-
- Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 2002;166:173–177. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
